Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported with funding from Prothena (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ISA 2020 | The value of screening biopsies in AL & ATTR amyloidosis

Oliver Charles Cohen • 15 Sep 2020
ISA 2020
Amyloidosis Rare Diseases

Oliver Charles Cohen, MD, University College London Hospitals NHS Foundation Trust, London, UK, talks on the value of screening biopsies in light-chain (AL) and transthyretin (ATTR) amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Oliver Charles Cohen

Post-renal transplantation hematological response assessment: AL amyloidosis
4:05
Post-renal transplantation hematological response assessment: AL amyloidosis
Oliver Charles Cohen • 16 Sep 2020
Lenalidomide and Ixazomib: a successful amyloidosis treatment combination?
4:28
Lenalidomide and Ixazomib: a successful amyloidosis treatment combination?
Oliver Charles Cohen • 14 Sep 2019

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Oliver Charles Cohen • 7 Dec 2025
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
2:25
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Oliver Charles Cohen • 5 Dec 2025
Investigating novel therapeutic approaches for T-cell lymphoma
1:01
Investigating novel therapeutic approaches for T-cell lymphoma
Oliver Charles Cohen • 8 Dec 2025
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
3:45
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
Oliver Charles Cohen • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals